**Name of Journal: *World Journal of Gastrointestinal Oncology***

**ESPS Manuscript NO: 27826**

**Manuscript Type: Minireviews**

[**Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature**](http://www.wjgnet.com/esps/ManuscriptDetail.aspx?id=G9085n0%2fWVM9FltO%2bIWdrQ%3d%3d)

Ghosn M *et al*.Chemotherapy for ampullary carcinoma

**Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Fady Ghassan Haddad, Colette Hanna, Fadi El Karak, Dolly Nasr**

**Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Fady Ghassan Haddad, Colette Hanna, Fadi El Karak,** Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut 1104-2020, Lebanon

**Hampig Raphael Kourie,** Department of Oncology, Jules Bordet Institute, Free University of Brussels (ULB), B-1070 Brussels, Belgium

**Dolly Nasr,** Department of Radiation Oncology, Faculty of Medicine, Saint Joseph University, Beirut 1104-2020, Lebanon

**Author contributions:** Ghosn M initiated the review; Ghosn M, Kourie HR, El Rassy E performed the review, analyzed the data and wrote first draft; Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F and Nasr D reviewed and commented on the paper and provided final approval.

**Conflict-of-interest** **statement:** To the best of our knowledge, no conflict of interest exists.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Marwan Ghosn, MD,** Department of Oncology, Faculty of Medicine, Saint Joseph University, Monot St, Beirut, PO Box 166830, Beirut 1104-2020, Lebanon. mghosn.hdf@usj.edu.lb

**Telephone:** +961-1-3226842

**Fax:** +961-1-1613397

**Received:** June 18, 2016

**Peer-review started:** June 19, 2016

**First decision:** July 4, 2016

**Revised:** July 29, 2016

**Accepted:** August 17, 2016

**Article in press:**

**Published online:**

**Abstract**

Ampullary carcinoma (AC) is a rare gastrointestinal tumor without clear treatment recommendations. The management of these tumors is usually extrapolated from the treatment of pancreatic, biliary duct and intestinal cancers. Few papers have studied the AC as an independent entity and their limitations are several. These studies were retrospective single institutional experiences with limited sample sizes recruited over a long period of time. Unlike metastatic ACs where chemotherapy is the only recommended option, localized AC once excised may be approached by either chemotherapy alone or concomitant chemoradiation therapy. In this review, we report the overall survival and recurrence factors of more than 1000 patients from all the studies treating exclusively ACs. We also review the medical treatment of this tumor and conclude to the necessity of multi-institutional randomized controlled studies for AC exclusively.

**Key words**: Ampullary cancer; Review; Prognostic factors; Treatment; Novel therapies

© **The Author(s) 2016**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This paper is a minireview outlining the actual knowledge concerning the treatment of ampullary carcinoma. After a brief review of the prognostic factors and current treatment options for localized and advanced ampullary carcinoma, we discuss the new molecular targets and report on the potential novel therapies.

Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D. [Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature](http://www.wjgnet.com/esps/ManuscriptDetail.aspx?id=G9085n0%2fWVM9FltO%2bIWdrQ%3d%3d). *World J Gastrointest Oncol* 2016; In press

**INTRODUCTION**

Ampullary carcinoma (AC) is an uncommon tumor accounting for approximately 0.2% of gastrointestinal malignancies and 7% of periampullary tumors[1]. It is continuously increasing in frequency and actually is the second most common of periampullary tumors after pancreatic cancers[1,2]. Adenocarcinomas are the most common tumors of the ampulla and may be subdivided pathologically into intestinal and pancreaticobiliary subtypes for potential prognostic purposes[3]. Few trials have studied the AC as an independent entity. It is frequently seen as a subgroup of pancreatic and biliary tract cancer trials even though ACs have a better prognosis and constitute a confounding factor in these studies. In comparison to pancreatic adenocarcinomas, prognostic factors are in favor of the ampullary tumors. The tumor size and staging at diagnosis, the positivity of lymph nodes (LN), the vascular and neural invasions were lower in ACs[4]. Nevertheless, trials treated ACs as pancreatic cancers. This dilemma probably stands essential for the absence of any guidelines from both the National Care Cancer Network (NCCN) and the European Society for Medical Oncology(ESMO) concerning the treatment of advanced ACs[5,6]. In this paper we report on the recurrence factors and overall survival (OS) of patients with AC. We also review the position of chemotherapy in this setting.

**PROGNOSTIC FACTORS IN AC**

Although localized AC is known for its high rates of resectability and good long term OS, most of the series report a high proportion of recurrent disease. However, these series are of small numbers which disables any statistical OS analysis[1]. LN spreading and number of resection LV[7-12], the vascular, nervous and pancreatic invasion[7,11-15] along with the unresectability of the tumor and positive margin status after resection[9,10,13,16], and intraoperative transfusions[7,11,17] are the most consistent survival factors throughout the studies of localized AC.

Several studies tried to establish the risk factors for the recurrences of excised ACs. Todoroki *et al*[14] in 2003 did not experience locoregional failure with pancreaticoduodenectomy. Recurrences occurred distally and were affected by lymphatic and venous invasion with a mean time to relapse of 13 mo. Perioperative blood transfusion, LN spreading and pancreatic invasion increased the risk of recurrence[7,11,17].

Very few studies elaborated the prognostic factors of advanced ACs. These factors can be extrapolated from studies of unresectable pancreatic and periampullary cancers. Negative prognostic factors include weight loss, abdominal pain, peritoneal dissemination and liver metastasis. Older age is also a negative prognostic factor except in white younger women characterized by a worse prognosis than older ones[18,19].

**EVOLUTION OF TREATMENTS**

Tumor resection is the mainstay in the treatment of localized AC. Current surgical options prefer radical pancreaticoduodenectomy over local resection despite its higher morbidity[7]. The conventional local regional resection technique considers a transduodenal approach. The extraduodenal technique is a potential alternative that offers a complete removal of the tumor with concurrent excision of retropancreatic LN[20]. Preoperative endoscopic biliary drainage is not widely acceptable among pancreatic surgeons in view of the increased morbidity and delays of definite treatment[21]. However, the only study involving AC exclusively showed that preoperative biliary drainage reduces postoperative wound infection without influencing mortality[22].

The role of chemotherapy for both local and advanced AC is not yet clearly established in view of the rarity of the disease. The only relevant data is commonly found in series combining patients with small bowel, pancreatic or biliary tract tumors. Tables 1 and 2 report the response rate, time to progression and OS of 10 retrospective single institutional experience of small sample sizes varying between 26 and 186 patients with AC that were recruited over periods ranging from 5 to 33 years.

While reviewing the localized AC studies, most of the series used a pancreatic cancer chemotherapy regimen that consisted of fluorouracil and radiotherapy to treat ACs[23-29]. Regimens also combined gemcitabine and radiotherapy after the introduction of the first in 1997[30]. The ESPAC-3 trial by Neoptolemos *et al*[31] in 2012 included the largest sample of AC patients; 297 of the 428 patients enrolled in this trial had AC. Participants were divided into three subgroups: The control group consisted of 144 patients, the fluorouracyl and the gemcitabine subgroups contained 143 and 141 patients respectively. Overall, the increase in median OS in the chemotherapy group was not statistically significant (43.1 v/s 35.2 mo; *P* = 0.25)[31]. By analyzing exclusively AC data, the median OS of the gemcitabine and the fluorouracyl subgroups were 71 mo and 57.8 mo respectively in comparison to the 41 mo of the control arm group[31]. In opposition, Jiang *et al*[30] in 2013 showed a trend toward increased OS in the fluorouracyl group.

Papers reporting treatments of advanced ACs are fewer, only two papers were published to date[32,33]. The first introduced in 2010 platinum for the first time in the treatment of AC; the regimens consisted of a combination of cisplatin with either gemcitabine or fluorouracyl but failed to establish any OS difference between the two protocols[32]. In opposition, Shoji *et al*[33] showed more OS benefit in the gemcitabine group. This study reported 26 advanced AC patients receiving chemotherapy without tumor resection. The fluorouracil and gemcitabine based protocols had a response rate of 7.7% and an OS of 9.1 mo (OS = 9 and 12.3 mo respectively). It is of particular importance to note a phase II trial by Overman *et al*[34] that recruited 30 patients among which 40% had advanced AC. Patients received a treatment with capecitabine and oxaliplatin (CAPOX) and had an overall response rate of 33% (95%CI: 10%-65%)[34].

**CONCURRENT CHEMOTHERAPY TREATMENTS IN LOCALIZED AC**

In the absence of solid data, neither NCCN nor ESMO established standard chemotherapy regimens for patients with ACs[5,6]. Effectively, the Americans approach this tumor differently than the Europeans (Figure 1)[35].

In discordance with the European treatment regimens that extrapolate chemotherapy protocols from pancreatic tumor trials[30,31,36], the American treatment regimen is supported by the result of RTOG 9704 trial[37]. As of stage IB of AC, the treatment approach is identical to resectable pancreatic adenocarcinomas with a sequence of gemcitabine and concurrent infusional fluorouracyl and radiotherapy. Though the optimal sequencing is not clear, an acceptable protocol includes gemcitabine 1000 mg/m2 for 3 weekly followed by conformal radiotherapy with concurrent infusional fluorouracyl 250 mg/m2 daily, and after 3 to 5 wk gemcitabine is reintroduced at 1000 mg/m2 for 3 of every 4 wk for 3 mo[38]. As with pancreatic cancer, the infusion protocol of fluorouracil is not clear yet.

**CONCURRENT CHEMOTHERAPY TREATMENTS IN ADVANCED AC**

As with localized AC, the optimal chemotherapy is not yet elucidated. The concurrent chemotherapy regimenrecommended in advanced AC is an association of cisplatin and gemcitabine[38]. Other acceptable regimens adopted from the pancreatic chemotherapy treatment panel are fluorouracyl or gemcitabine associated with oxaliplatin[37-40]. An interesting approach in this context considers the pathologic subtype as an indicator for a potential chemotherapy regimen where fluorouracyl-based therapy is used for intestinal ACs and gemcitabine-based therapy for pancreaticobiliary ACs[34].

**NOVEL THERAPIES**

Given the rarity of the disease, the performance of well-powered randomized controlled clinical trials is very difficult. Multiple phase II trials including targeted therapies are actually ongoing among which a combination of CAPOX and bevacizumab (NCT01208103), CAPOX and panitumumab (NCT01202409), gemcitabine-oxaliplatin (GEMOX) and erlotinib (NCT00832637). The only study ongoing in the adjuvant setting is evaluating the role of high volume washing of the abdomen in increasing survival after surgery in patients with pancreatic and peripancreatic tumors (NCT02757859).

The ongoing studies seem promising but recruit also other peripancreatic tumors besides AC. A recentgenomic sequencing study of ACidentified severe genetic aberrations with deleterious mutations and deletions in KRAS, SMAD4 and PTEN. This genomic profile suggests that the oncogensis of ACs differs from both biliary tract and pancreatic cancers. The combination of these genomic aberrations suggests a therapeutic approach by mTOR/PI3K inhibition for patients with AC[41]. Moreover, another genomic analysis revealed mutations in the WNT signaling pathway with high frequency inactivating mutations of ELF3 and a high rate of microsatellite instability. Such findings coupled with small-molecule inhibitors of β-catenin would be of particular interest to be evaluated in clinical trials[42]. The only ongoing genetic analysis-guided dosage treatment study of patients with advanced gastroinstestinal cancer include a combination of nab-paclitaxel, fluorouracyl, leucovorin and irinotecan (FOLFIRABAX) (NCT02333188).

**CONCLUSION**

Given the rarity of the ACs, the published literature lacks well-powered randomized controlled trials. Effectively, the published data is limited to single institutional retrospective studies with small sample sizes. These studies recommend gemcitabine monotherapy or in combination with conformal radiotherapy for the treatment of localized AC and the combination of gemcitabine and cisplatin for the treatment of advanced AC. While analyzing these data, one should be aware to the selection bias of retrospective studies. Moreover, the results of single institutional studies are not to be extrapolated to community hospitals where the surgeons are less experienced in the management of this rare disease. Any effort for future therapeutic development should consider multi-institutional randomized controlled studies recruiting exclusively AC.

**REFERENCES**

1 **O'Connell JB**, Maggard MA, Manunga J, Tomlinson JS, Reber HA, Ko CY, Hines OJ. Survival after resection of ampullary carcinoma: a national population-based study. *Ann Surg Oncol* 2008; **15**: 1820-1827 [PMID: 18369675 DOI: 10.1245/s10434-008-9886-1]

2 **Albores-Saavedra J**, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. *J Surg Oncol* 2009; **100**: 598-605 [PMID: 19697352 DOI: 10.1002/jso.21374]

3 **Chang DK**, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. *J Clin Oncol* 2013; **31**: 1348-1356 [PMID: 23439753 DOI: 10.1200/JCO.2012.46.8868]

4 **Morris-Stiff G**, Alabraba E, Tan YM, Shapey I, Bhati C, Tanniere P, Mayer D, Buckels J, Bramhall S, Mirza DF. Assessment of survival advantage in ampullary carcinoma in relation to tumour biology and morphology. *Eur J Surg Oncol* 2009; **35**: 746-750 [PMID: 19167859 DOI: 10.1016/j.ejso.2008.10.010]

5 **National Comprehensive Cancer Network**. NCCN Clinical practice guidelines in oncology. [accessed 2014 Apr 1]. Available from: URL: http: //www.nccn.org/professionals/physician\_gls/f\_guidelines.asp

6 **Eckel F**, Jelic S. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. *Ann Oncol* 2009; **20** Suppl 4: 46-48 [PMID: 19454460 DOI: 10.1093/annonc/mdp125]

7 **Balachandran P**, Sikora SS, Kapoor S, Krishnani N, Kumar A, Saxena R, Kapoor VK. Long-term survival and recurrence patterns in ampullary cancer. *Pancreas* 2006; **32**: 390-395 [PMID: 16670621 DOI: 10.1097/01.mpa.0000220864.80034.63]

8 **Klempnauer J**, Ridder GJ, Pichlmayr R. Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head. *Br J Surg* 1995; **82**: 1686-1691 [PMID: 8548242 DOI: [10.1002/bjs.1800821233](http://dx.doi.org/10.1002/bjs.1800821233)]

9 **Shirai Y**, Ohtani T, Hatakeyama K. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. *Br J Surg* 1996; **83**: 1302-1303 [PMID: 8983635 DOI: [10.1002/bjs.1800830940](http://dx.doi.org/10.1002/bjs.1800830940)]

10 **Howe JR**, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. *Ann Surg* 1998; **228**: 87-94 [PMID: 9671071 DOI: [10.1097/00000658-199807000-00013](http://dx.doi.org/10.1097/00000658-199807000-00013)]

11 **Hsu HP**, Yang TM, Hsieh YH, Shan YS, Lin PW. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. *Ann Surg Oncol* 2007; **14**: 50-60 [PMID: 17054003 DOI: 10.1245/s10434-006-9136-3]

12 **Qiao QL**, Zhao YG, Ye ML, Yang YM, Zhao JX, Huang YT, Wan YL. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. *World J Surg* 2007; **31**: 137-143; discussion 144-146 [PMID: 17171495 DOI: 10.1007/s00268-006-0213-3]

13 **Nakai T**, Koh K, Kawabe T, Son E, Yoshikawa H, Yasutomi M. Importance of microperineural invasion as a prognostic factor in ampullary carcinoma. *Br J Surg* 1997; **84**: 1399-1401 [PMID: 9361598 DOI: [10.1002/bjs.1800841017](http://dx.doi.org/10.1002/bjs.1800841017)]

14 **Todoroki T**, Koike N, Morishita Y, Kawamoto T, Ohkohchi N, Shoda J, Fukuda Y, Takahashi H. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. *Ann Surg Oncol* 2003; **10**: 1176-1183 [PMID: 14654474 DOI: [10.1245/ASO.2003.07.512](http://dx.doi.org/10.1245/ASO.2003.07.512)]

15 **Carter JT**, Grenert JP, Rubenstein L, Stewart L, Way LW. Tumors of the ampulla of vater: histopathologic classification and predictors of survival. *J Am Coll Surg* 2008; **207**: 210-218 [PMID: 18656049 DOI: 10.1016/j.jamcollsurj.2008.01028]

16 **Winter JM**, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. *J Gastrointest Surg* 2010; **14**: 379-387 [PMID: 19911239 DOI: 10.1007/s11605-00901080-7]

17 **Kim RD**, Kundhal PS, McGilvray ID, Cattral MS, Taylor B, Langer B, Grant DR, Zogopoulos G, Shah SA, Greig PD, Gallinger S. Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. *J Am Coll Surg* 2006; **202**: 112-119 [PMID: 16377504 DOI: 10.1016/j.jamcollsurg.2005.08.002]

18 **Terwee CB**, Nieveen Van Dijkum EJ, Gouma DJ, Bakkevold KE, Klinkenbijl JH, Wade TP, van Wagensveld BA, Wong A, van der Meulen JH. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study. Triple-P study group. *Eur J Surg* 2000; **166**: 706-712 [PMID: 11034467 DOI: 10.1080/110241500750008466]

19 **Fujino Y**, Suzuki Y, Ajiki T, Tanioka Y, Ku Y, Kuroda Y. Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline. *Hepatogastroenterology* 2003; **50**: 250-253 [PMID: 12630033]

20 **Zhao XQ**, Huang XQ, Zhang WZ, Liu Z. Comparison between two types of local resection in the treatment of ampullary cancer. *ANZ J Surg* 2014; **84**: 255-259 [PMID: 23347402 DOI: 10.1111/ans.12047]

21 **Lai EC**, Lau SH, Lau WY. The current status of preoperative biliary drainage for patients who receive pancreaticoduodenectomy for periampullary carcinoma: a comprehensive review. *Surgeon* 2014; **12**: 290-296 [PMID: 24650759 DOI: 10.1016/j.surge.2014.02.004]

22 **Abdullah SA**, Gupta T, Jaafar KA, Chung YF, Ooi LL, Mesenas SJ. Ampullary carcinoma: effect of preoperative biliary drainage on surgical outcome. *World J Gastroenterol* 2009; **15**: 2908-2912 [PMID: 19533815 DOI: [10.3748/wjg.15.2908](http://dx.doi.org/10.3748/wjg.15.2908)]

23 **Lee JH**, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, Rosato EF. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. *Int J Radiat Oncol Biol Phys* 2000; **47**: 945-953 [PMID: 10863064 DOI: [10.1016/S0360-3016(00)00537-X](http://dx.doi.org/10.1016/S0360-3016%2800%2900537-X)]

24 **Sikora SS**, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R, Kapoor VK. Adjuvant chemo-radiotherapy in ampullary cancers. *Eur J Surg Oncol* 2005; **31**: 158-163 [PMID: 15698732 DOI: 10.1016/j.ejso.2004.08.013]

25 **Bhatia S**, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. *Int J Radiat Oncol Biol Phys* 2006; **66**: 514-519 [PMID: 16863684 DOI: 10.1016/j.ijrobp.2006.04.018]

26 **Krishnan S**, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. *Int J Radiat Oncol Biol Phys* 2008; **70**: 735-743 [PMID: 17980502 DOI: 10.1016/j.ijrobp.2007.07.2327]

27 **Kim K**, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. *Int J Radiat Oncol Biol Phys* 2009; **75**: 436-441 [PMID: 19394162 DOI: 10.1016/j.ijrobp.2008.11.067]

28 **Narang AK**, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. *Radiat Oncol* 2011; **6**: 126 [PMID: 21951377 DOI: 10.1186/1748-717X-6-126]

29 **Palta M**, Patel P, Broadwater G, Willett C, Pepek J, Tyler D, Zafar SY, Uronis H, Hurwitz H, White R, Czito B. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. *Ann Surg Oncol* 2012; **19**: 1535-1540 [PMID: 22045467 DOI: 10.1245/s10434-011-2117-1]

30 **Jiang ZQ**, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. *Ann Oncol* 2013; **24**: 2349-2353 [PMID: 23704197 DOI: 10.1093/annonc/mdt191]

31 **Neoptolemos JP**, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA* 2012; **308**: 147-156 [PMID: 22782416 DOI: 10.1001/jama.2012.7352]

32 **Kim ST**, Lee J, Lee KT, Lee JK, Lee KH, Choi SH, Heo JS, Choi DW, Park SH, Park JO, Lim HY, Park YS, Kang WK. The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. *Med Oncol* 2010; **27**: 1149-1154 [PMID: 19898973 DOI: 10.1007/s12032-009-9351-4]

33 **Shoji H**, Morizane C, Hiraoka N, Kondo S, Ueno H, Ohno I, Shimizu S, Mitsunaga S, Ikeda M, Okusaka T. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy. *Jpn J Clin Oncol* 2014; **44**: 324-330 [PMID: 24482413 DOI: 10.1093/jjco/hyt237]

34 **Overman MJ**, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. *J Clin Oncol* 2009; **27**: 2598-2603 [PMID: 19164203 DOI: 10.1200/JCO.2008.19.7145]

35 **Ryan D**, Mamon H, Castillo CF. Ampullary carcinoma: Treatment and prognosis (Internet). 2014. Available from: URL: http://www.uptodate.com/home

36 **Oettle H**, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* 2007; **297**: 267-277 [PMID: 17227978 DOI: 10.1001/jama.297.3.267]

37 **Heinemann V**, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. *BMC Cancer* 2008; **8**: 82 [PMID: 18373843 DOI: 10.1186/1471-2407-8-82]

38 **Regine WF**, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. *JAMA* 2008; **299**: 1019-1026 [PMID: 18319412 DOI: 10.1001/jama.299.9.1019]

39 **Heinemann V**, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 2006; **24**: 3946-3952 [PMID: 16921047 DOI: 10.1200/JCO.2005.05.1490]

40 **Xiong HQ**, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. *Cancer* 2008; **113**: 2046-2052 [PMID: 18756532 DOI: 10.1002/cncr.23810]

41 **Demeure MJ**, Craig DW, Sinari S, Moses TM, Christoforides A, Dinh J, Izatt T, Aldrich J, Decker A, Baker A, Cherni I, Watanabe A, Koep L, Lake D, Hostetter G, Trent JM, Von Hoff DD, Carpten JD. Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. *Genome Med* 2012; **4**: 56 [PMID: 22762308 DOI: 10.1186/gm357]

42 **Gingras MC**, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE, Pilarsky C, Grützmann R, Overman MJ, Jamieson NB, Van Buren G, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. *Cell Rep* 2016; **14**: 907-919 [PMID: 26804919 DOI: 10.1016/j.celrep.2015.12.005]

**P- Reviewer:** Li CF, Tantau A, Yang CH, Zimmer V **S- Editor:** Gong XM

 **L- Editor:** **E- Editor:**

**Table 1 Response rate, time to progression and survival in patients with localized AC**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | ***n*** | **Patient Characteristics** | **Protocols** | **OS** | **RR/TTP** |
| Lee *et al*[23] | 39 | 1988-1997 33%CRT | RT (48.7 Gy) with continuous/concurrent infusion of 5-FU | 3 yr: 55% | 3 yr: 54% DFS  |
| Sikora *et al*[24] | 113 | 1989-2000104 patients remained alive after surgery | RT (50.4 Gy) with concurrent 5-FU | OS: 30 mo1 yr: 79%3 yr: 43%5 yr: 33% | NC |
| Bhatia *et al*[25] | 125 | 1977-2005 | 29 patients: RT (50.4 Gy) with 5-FU 96 surgery  | 3.4 yr 1.6 yr  | NC |
| Krishnan *et al*[26] | 96 | 1990-200656% CRT  | RT (45 Gypreop or 50.4 Gy postop) with 5-FU (42%) or capecitabine (43%) | 25.2 mo in patients with CRT v/s 16.5 mo in control arm | NC |
| Kim *et al*[27] | 118 | 1991-200235% CRT  | RT (40 Gy) with 5-FU (day 1🡪3) every split course | 5 yr: 52.8% v/s 66.9% in the control arm | NC |
| Narang *et al*[28] | 186 | 1992-2007 | RT with 5-FU | 39.9 mo 2 yr: 62.4%5 yr: 39.1% | NC |
| Palta *et al*[29] | 137 | 1976-2009 | 61 CRT43 adjuvant18 neoadjuvant | 3 yr: 62% in CRT and 46% in adjuvant | Neoadjuvant: 28% pCR |
| Jiang *et al*[30] | 64 | 1992-2009 | 5-FU-based v/s gemcitabine based | 5-FU trend toward benefit for OS (*P* = 0.007) | 5-FU significant improvement for TTP  |

CRT: Chemoradiotherapy; NC: Not calculated; OS: Overall survival; RT: Radiotherapy; TTP: Time to progression.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.**  | ***n*** | **Patient characteristics** | **Protocols** | **OS** | **RR/TTP** |
| Kim *et al*[32] | 29 | 2003-2008 | 31% Cis + Gem69% Cis + 5-FU | 12.5 mo (no significant difference between the two groups) | NC |
| Shoji *et al*[33] | 26 | 1997-2010 | 5-FU-based gemcitabine-based | OS = 9.1 mo 8 mo12.3 mo | RR = 7.7% |

**Table 2 Response rate, time to progression and survival in patients with advanced**

Cis: Cisplatin; Gem: Gemcitabine; NC: Not calculated; OS: Overall survival; RR: Response rate; TTP: Time to progression.



**Figure 1 Concurrent American and European approach for the treatment of localized ampullary carcinoma[35].**